| Literature DB >> 33398501 |
Oliver Hommerding1, Yves Allory2, Pedram Argani3, Tarek A Bismar4, Lukas Bubendorf5, Sofía Canete-Portillo6, Alcides Chaux7, Ying-Bei Chen8, Liang Cheng9, Antonio L Cubilla10, Lars Egevad11, Anthony J Gill12,13,14, David J Grignon15, Arndt Hartmann16, Ondrej Hes17, Muhammad T Idrees18, Chia-Sui Kao19, Margaret A Knowles20, Leendert H J Looijenga21, Tamara L Lotan22, Colin C Pritchard23, Mark A Rubin24, Scott A Tomlins25, Theodorus H Van der Kwast26, Elsa F Velazquez27, Joshua I Warrick28, Sean R Williamson29,30, Glen Kristiansen31.
Abstract
Comprehensive understanding of molecular principles in cancer and the diversification of oncological therapy promise individual therapeutic concepts, which have not yet found their way into urogenital cancer therapy. In March 2019 the International Society of Urogenital Pathology (ISUP) therefore held a consensus conference on recommendations for molecular diagnostics of genitourinary tumors, which were published in five separate manuscripts and are summarized in this article.In preparation for the conference, a comprehensive survey of current practices for molecular testing of urogenital tumors was carried out by members of the ISUP. At the conference, the results and the corresponding background information were presented by five working groups and recommendations for action for diagnostics were developed. An agreement between 66% of the conference participants was defined as consensus.Entities:
Keywords: Bladder cancer; Kidney cancer; Molecular biomarker; Prostate cancer; Targeted therapy
Mesh：
Year: 2021 PMID： 33398501 DOI： 10.1007/s00292-020-00888-4
Source DB: PubMed Journal: Pathologe ISSN： 0172-8113 Impact factor: 1.011